Exelixis (EXEL) Gains from Investment Securities (2010 - 2026)
Exelixis (EXEL) recorded quarterly Gains from Investment Securities of $34.2 million in Q2 2026, up 162.48% quarter-over-quarter from -$54.8 million in Q1 2026, and up 52.03% on a YoY basis from $22.5 million in Q2 2025.
Exelixis (EXEL) Gains from Investment Securities (2010 - 2026) Analysis & Trends
Exelixis' Gains from Investment Securities history runs 17 years deep, the most recent figure standing at $34.2 million for Q2 2026.
- In Q2 2026, Gains from Investment Securities rose 52.03% year-over-year to $34.2 million; the TTM figure through Apr 2026 stood at $23.3 million (down 87.46% YoY), while the FY2026 annual figure was $11.6 million, down 93.19% from the prior year.
- Gains from Investment Securities was $34.2 million for Q2 2026 at Exelixis, up from -$54.8 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $161.2 million in Q1 2025 to a low of -$54.8 million in Q1 2026.
- Historically, Gains from Investment Securities has averaged $15.1 million across 5 years, with a median of $6.5 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities slumped 400.5% in 2024, then jumped 3543.73% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $7.2 million in 2022, then plunged by 38.62% to $4.4 million in 2023, then tumbled by 237.08% to -$6.1 million in 2024, then soared by 1019.52% to $55.8 million in 2025, then sank by 38.63% to $34.2 million in 2026.
- The last three Gains from Investment Securities figures came in at $34.2 million (Q2 2026), -$54.8 million (Q1 2026), and $55.8 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Exelixis | 13.61 Bn | 12.83 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 34.23 Mn |
| Apr 3, 2026 | 34.23 Mn |
| Jan 2, 2026 | -54.79 Mn |
| Jan 2, 2026 | -54.79 Mn |
| Oct 3, 2025 | 55.78 Mn |
| Oct 3, 2025 | 55.78 Mn |
| Jul 4, 2025 | -11.90 Mn |
| Jul 4, 2025 | -11.90 Mn |
| Apr 4, 2025 | 22.52 Mn |
| Apr 4, 2025 | 22.52 Mn |
| Jan 3, 2025 | 161.24 Mn |
| Jan 3, 2025 | 161.24 Mn |
| Sep 27, 2024 | -6.07 Mn |
| Sep 27, 2024 | -6.07 Mn |
| Jun 28, 2024 | 8.33 Mn |
| Jun 28, 2024 | 8.33 Mn |
| Mar 29, 2024 | 6.99 Mn |
| Mar 29, 2024 | 6.99 Mn |
| Dec 29, 2023 | 4.43 Mn |
| Dec 29, 2023 | 4.43 Mn |